Studies Examine Cost-Effectiveness of Maternal RSV Vaccination, Nirsevimab in Infants

MONDAY, Nov. 25, 2024-- Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.David W. Hutton, Ph.D., from the...